We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Influenza and Streptococcus Tests Get FDA Clearance

By LabMedica International staff writers
Posted on 07 Nov 2018
Each year, a combination of influenza A and B virus strains circulate within the USA. The burden of influenza in the USA is currently estimated to be 9 to 36 million cases per year. The disease and its complications cause as many as 140,000 to 710,000 hospitalizations and 12,000 to 56,000 deaths annually. Influenza also poses a significant economic burden including medical care expenses and loss of productivity.

Pharyngitis, or inflammation of the pharynx causing sore throat, is diagnosed in 11 million patients in USA emergency departments and ambulatory settings annually. Group A Streptococcus (GAS) is the most common bacterial cause of acute pharyngitis, accounting for 15% to 30% of cases in children and 5% to 20% of cases in adults. GAS is easily and frequently spread among families and other close contacts via respiratory secretions, and infection peaks in the late winter and early spring.

The US Food and Drug Administration (Silver Springs, MS, USA) have cleared next-generation Influenza A & B 2 and Strep A 2 molecular assays for point-of-care testing. The new assays enable fast time-to-results for molecular influenza A & B and Strep A testing at the point of care. Both assays have also been granted CLIA waivers and are available for use with the Abbott ID Now platform, formerly the Alere I, a rapid, instrument-based, isothermal nucleic acid amplification system for the qualitative detection of infectious diseases.

The Influenza A & B 2 assay provides point-of-care molecular detection and differentiation of influenza A and B virus in 13 minutes or less, and it calls out positive results in five minutes. The assay enables room temperature storage of all test components, which simplifies and streamlines test ordering and storage. The Strep A 2 test provides molecular detection of group A Streptococcus bacterial nucleic acid, the primary cause of bacterial pharyngitis, or sore throat, in six minutes or less, and it calls out positive results in two minutes. Culture confirmation is not required for negative results.

Gregory Berry, PhD, D(ABMM), director of molecular diagnostics at Northwell Health Laboratories (Lake Success, NY, USA), said, "Rapid testing may also help reduce improper antibiotic usage, which can occur when treatment is based exclusively on a patient's symptoms, and contributes to antibiotic resistance.”

Related Links:
US Food and Drug Administration
Northwell Health Laboratories


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
High Performance Centrifuge
CO336/336R
New
Vaginitis Test
Allplex Vaginitis Screening Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.